News &amp; Updates

Use of etomidate for rapid sequence intubation (RSI) does not appear to increase the incidence of secondary infection, a study has shown.

Etomidate use for RSI not linked to nosocomial infection

CVD prevention better with ACE inhibitor–statin combo than monotherapy

In patients with hypertension, combined treatment with angiotensin-converting enzyme (ACE) inhibitors plus statins reduces the risk of developing cardiovascular disease (CVD) at a greater magnitude as compared with ACE inhibitor monotherapy, a study has found.

CVD prevention better with ACE inhibitor–statin combo than monotherapy

08 Jul 2022

Testosterone therapy safe for the heart, but some experts disagree

08 Jul 2022 by

Testosterone therapy appeared safe for the heart in men with hypogonadism, according to a meta-analysis of 35 placebo-controlled trials presented at ENDO 2022. However, experts have differing opinions on the findings.

Testosterone therapy safe for the heart, but some experts disagree

L-MOCA: Olaparib maintenance for ovarian cancer benefits Asians

Maintenance monotherapy with olaparib appears safe and effective in Asian patients with platinum-sensitive relapsed (PSR) ovarian cancer, regardless of their BRCA status, as shown in the results of the phase III, open-label, single-arm L-MOCA study.

L-MOCA: Olaparib maintenance for ovarian cancer benefits Asians

07 Jul 2022

CC genotype ups risk for azathioprine cessation

The risk for azathioprine discontinuation attributed to haematopoietic toxicity and lower thiopurine doses is higher among patients with the rs2814778-CC genotype, reveals a study. Genotype remains associated with the risk even after adjustment for race.

CC genotype ups risk for azathioprine cessation

RA patient’s perspective must be respected in treatment decisions, says study

Physician-reported measures on responses to tofacitinib and adalimumab treatments are higher than those reported by patients with rheumatoid arthritis (RA), according to a post hoc analysis of data from phase III and phase IIIb/IV trials.

RA patient’s perspective must be respected in treatment decisions, says study

07 Jul 2022

Post-transplant KRd a new SoC for MM?

In the ongoing phase III ATLAS study evaluating patients with newly diagnosed multiple myeloma (MM), progression-free survival (PFS) was better with maintenance treatment with carfilzomib, lenalidomide, and dexamethasone (KRd) than lenalidomide (R) alone after autologous stem-cell transplantation (ASCT).

Post-transplant KRd a new SoC for MM?

07 Jul 2022

Transmembrane modulators of CFTR gene leads to improvements in kids with cystic fibrosis

Using small molecule drugs to modulate the cystic fibrosis transmembrane conductance regulator (CFTR) protein improves multiple aspects of cystic fibrosis in paediatric patients, including lung function, CFTR protein function, and nutritional status, according to a recent meta-analysis.

Transmembrane modulators of CFTR gene leads to improvements in kids with cystic fibrosis

$Ganaxolone drip safe, affords seizure control in patients with refractory status epilepticus$

Ganaxolone drip safe, affords seizure control in patients with refractory status epilepticus

Treatment with intravenous ganaxolone induces rapid and durable seizure control in patients with refractory status epilepticus, while showing acceptable safety and tolerability, according to the results of an open-label phase II trial.

Ganaxolone drip safe, affords seizure control in patients with refractory status epilepticus

Intranasal corticosteroids yield no clinically meaningful improvement in paediatric OSAS

In the treatment of children with obstructive sleep apnoea syndrome (OSAS), use of intranasal corticosteroids falls short of producing substantial changes in symptoms as well as in polysomnographic and neurobehavioural parameters at 3 and 12 months, a study has found.

Intranasal corticosteroids yield no clinically meaningful improvement in paediatric OSAS